Aktuellt
SENASTE
Redeye sees BioArctic's stock price reaction as a result of the European Medicines Agency (EMA) probably rejecting Biogen's aducanumab - as exaggerated. The two antibodies have a different design, clinical profile and dataset. They must be seen on their own merits. EMA's potential aducanumab rejection does not impact lecanemab's likelihood of approval, and we would like to caution investors from correlating the destiny of the two antibodies and the stock price of the respective companies.
LÄS MER
